FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
1.360
-0.070 (-4.90%)
At close: Apr 28, 2026, 4:00 PM EDT
1.380
+0.020 (1.47%)
After-hours: Apr 28, 2026, 7:24 PM EDT
FibroBiologics Stock Forecast
FBLG's stock price has decreased by -94.43% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for FibroBiologics stock has a target of 8.00, which predicts an increase of 488.24% from the current stock price of 1.36.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for FibroBiologics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 → $8 | Strong Buy | Maintains | $4 → $8 | +488.24% | Apr 16, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $140 | Strong Buy | Maintains | $140 | +10,194.12% | Mar 12, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $100 → $80 | Strong Buy | Maintains | $100 → $80 | +5,782.35% | Feb 26, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $300 → $140 | Strong Buy | Maintains | $300 → $140 | +10,194.12% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.09
from -8.35
EPS Next Year
-4.18
from -4.09
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.98 | -1.55 | ||||||
| Avg | -4.09 | -4.18 | ||||||
| Low | -5.68 | -7.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.